

Emerging trends in drug discovery: Harnessing artificial intelligence and machine learning for drug development

Priya Khandagale

Department of Bioinformatics, Deogiri College, Aurangabad, Maharashtra, India.

Correspondence:

Priya Khandagale, Department of Bioinformatics, Deogiri College, Aurangabad - 431 001, Maharashtra, India. E-mail: priyakhandalenov@gmail.com

How to cite this article:

Khandagale P. Emerging trends in drug discovery: Harnessing artificial intelligence and machine learning for drug development. Innov Pharm Planet (IP-Planet) 2024;12(3):56-61.

Source of Support: Nil.

Conflicts of Interest: None declared.

Date of Submission: 20-08-2024

Date of Revision: 15-09-2024

Date of Acceptance: 19-09-2024

ABSTRACT

The traditional drug discovery process is a resource-intensive, time-consuming, and expensive endeavor, often characterized by high failure rates and inefficiencies. Recent advancements in artificial intelligence (AI) and machine learning (ML) have introduced revolutionary tools that are transforming the pharmaceutical industry, enabling faster, more cost-effective, and precise drug development. This review examines the transformative role of AI and ML across key stages of drug discovery, including target identification, compound screening, lead optimization, and clinical trials. AI/ML technologies leverage vast biological datasets and employ advanced algorithms such as neural networks, natural language processing, and reinforcement learning to enhance the efficiency and accuracy of drug discovery pipelines. These tools enable the identification of novel drug targets, accurate prediction of drug efficacy and safety profiles, and optimization of clinical trial designs, substantially reducing development timelines and costs. Real-world case studies highlight the success of AI/ML in delivering breakthrough therapies in areas such as oncology, neurodegenerative diseases, and rare genetic disorders. Despite these advancements, several challenges persist, including issues related to data quality, model interpretability, algorithmic bias, and regulatory compliance. Furthermore, ethical considerations surrounding data privacy, transparency, and decision-making in AI-driven processes are critical to address. This review also explores emerging trends, such as the integration of multi-omics datasets, advancements in quantum computing, and the growing focus on personalized medicine and precision drug development. Overcoming current challenges through interdisciplinary collaboration, innovation, and the implementation of robust ethical frameworks will be essential for unlocking AI/ML's full potential, ushering in a new era of patient-centric and precision-driven drug discovery and development.

Keywords: Ayurvedic formulations, cancer therapy, drug discovery, natural products, neurodegenerative diseases

Introduction

Background on traditional drug discovery processes

Traditional drug discovery is a complex and lengthy process that typically spans 12 to 15 years and incurs costs exceeding \$1 billion. This conventional approach involves several stages, starting from target identification and validation, followed by hit identification,

lead optimization, and ultimately clinical trials. Historically, drug discovery relied heavily on serendipitous findings or the isolation of active compounds from natural sources. With advancements in technology, methods such as high-throughput screening of chemical libraries became prevalent, allowing researchers to identify potential drug candidates more systematically.^[1]

Despite these advancements, traditional drug discovery remains time-intensive and cost heavy. The reliance on trial-and-error experimentation often leads to prolonged timelines and high failure rates in clinical trials. Many compounds that show promise in early testing fail to demonstrate efficacy or safety in later stages, contributing to the overall inefficiency of the process. This situation has prompted a search for more efficient methodologies in drug development.^[2]

Access this article online

Website: <https://innovationaljournals.com/index.php/ip> **e-ISSN:** 2348-7275

DOI: 10.31690/ipplanet.2024.v012i03.016

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution NonCommercial Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Emergence of artificial intelligence/machine learning as transformative tools in healthcare

The emergence of Artificial Intelligence (AI) and Machine Learning (ML) represents a transformative shift in the healthcare landscape, particularly in drug discovery. AI technologies can analyze vast datasets quickly and accurately, identifying patterns that may elude human researchers. These technologies enhance the drug discovery process by improving efficiency and reducing costs associated with traditional methods. For instance, AI can predict the efficacy and toxicity of new compounds with greater accuracy than conventional approaches, streamlining the identification of viable drug candidates.

Moreover, AI can assist in drug-target identification by analyzing biological data to uncover new therapeutic targets. This capability expands the scope of drug discovery beyond traditional methods, potentially leading to novel treatments for complex diseases. As AI continues to evolve, its integration into pharmaceutical research is expected to accelerate the development of new medications while addressing existing challenges within the industry.^[3]

Scope of the review and its importance in the current research landscape

This review aims to explore the intersection of traditional drug discovery methods and emerging AI/ML technologies. By examining current research trends and applications of AI in drug discovery, it seeks to highlight both the opportunities and challenges presented by these innovative approaches. The importance of this review lies in its potential to inform researchers and industry stakeholders about how AI can complement existing methodologies, ultimately leading to more effective and efficient drug development processes.

In an era where healthcare demands are rapidly evolving, understanding the role of AI/ML in transforming drug discovery is crucial. This review will provide insights into how these technologies can address inefficiencies within traditional frameworks while fostering innovation in therapeutic development.^[4,5]

Overview of Artificial Intelligence and Machine Learning In Drug Discovery

Definition of artificial intelligence and machine learning

AI refers to the simulation of human intelligence in machines programmed to think and learn. In the context of drug discovery, AI encompasses a range of technologies that enable computers to analyze complex biological data, predict outcomes, and make decisions that enhance the efficiency of drug development. ML, a subset of AI, involves algorithms that allow systems to learn from data patterns without explicit programming. ML is particularly valuable in drug discovery for analyzing large datasets, identifying potential drug candidates, and predicting their biological activity.

Key differences between artificial intelligence, machine learning, and deep learning in the context of drug discovery

While AI and ML are often used interchangeably, they represent different concepts:

- AI is the overarching field that encompasses various technologies aimed at mimicking human cognitive functions.
- ML is a specific approach within AI that focuses on developing algorithms capable of learning from and making predictions based on data.
- Deep Learning (DL) is a further subset of ML that utilizes neural networks with multiple layers (deep architectures) to analyze complex datasets. In drug discovery, DL has shown significant promise in tasks such as predicting molecular interactions and optimizing drug design due to its ability to uncover intricate patterns within large volumes of data.

In summary, while all three terms are interconnected, they differ in scope and application within drug discovery processes.

Historical evolution of artificial intelligence and machine learning applications in pharmaceutical sciences

The application of AI and ML in pharmaceutical sciences has evolved significantly over the past few decades. Initially, traditional computational methods were employed for drug discovery, which involved labor-intensive processes such as quantitative structure-activity relationship (QSAR) modeling. However, these methods faced limitations due to their reliance on predefined rules and smaller datasets.

The introduction of ML algorithms in the early 2000s marked a turning point. These algorithms began to enhance predictive accuracy by learning from larger datasets generated during compound optimization. Over time, advancements in computational power and data availability led to the integration of more sophisticated techniques like DL.

By 2012, notable initiatives such as Merck's QSAR ML challenge demonstrated the advantages of DL models over traditional approaches in predicting drug-related properties. As a result, pharmaceutical companies increasingly adopted AI-driven methodologies for tasks like target identification, compound screening, and toxicity prediction.

Today, AI and ML are integral components of modern drug discovery pipelines. They facilitate accelerated drug design processes, optimize clinical trials, and even assist in repurposing existing drugs for new therapeutic uses.^[6] The ongoing evolution of these technologies continues to reshape the landscape of pharmaceutical sciences, promising more efficient pathways for developing effective therapeutics.

Applications of Artificial Intelligence and Machine Learning in Drug Discovery

Target identification and validation

AI and ML algorithms play a crucial role in identifying potential drug targets by analyzing extensive biological datasets, including genomics, proteomics, and clinical data. These algorithms can sift through various sources of information to predict which proteins or genes are involved in disease mechanisms, thereby highlighting novel targets for therapeutic intervention. For instance, DL models can utilize data from drug information banks and scientific literature to prioritize molecular targets effectively. In addition, integrating AI with structural prediction tools like Alpha Fold allows researchers to predict the three-dimensional structures of proteins, further aiding in target validation and the design of drugs that can bind effectively to these targets.

Compound screening and drug repurposing

AI-powered virtual screening techniques have revolutionized the compound screening process by enabling high-throughput analysis of large chemical libraries. ML models can predict the biological activity of compounds based on their chemical structure, significantly accelerating the identification of promising drug candidates.^[7] Furthermore, AI facilitates drug repurposing strategies by analyzing existing drugs and their interactions with new targets. By leveraging historical data on drug efficacy and safety profiles, ML models can suggest new therapeutic uses for established medications, thereby reducing development time and costs associated with bringing new drugs to market.

Drug design and optimization

AI-driven molecular design tools are transforming the way new drug candidates are developed. These tools utilize generative models to create novel molecules with desired pharmacological properties. For example, DL algorithms can analyze known compounds and their characteristics to propose new candidates that exhibit improved solubility or bioactivity.^[8] Generative adversarial networks have also been employed to design innovative drug candidates from scratch, demonstrating significant potential in accelerating the drug discovery process. This shift toward AI-enhanced drug design not only streamlines the development pipeline but also increases the likelihood of discovering effective therapies.

Preclinical and clinical trials

In preclinical and clinical trials, AI is increasingly being utilized to predict drug efficacy and safety profiles. ML models can analyze historical trial data to identify patterns that indicate how a new drug will perform in humans, thus enhancing the predictive accuracy of clinical outcomes. In addition, AI optimizes clinical trial designs by improving patient recruitment processes. By analyzing patient data and characteristics, ML algorithms can identify suitable candidates for trials more efficiently than traditional methods, ultimately leading to more successful trial outcomes.^[9] This integration of AI in clinical

research not only expedites the development timeline but also contributes to more personalized treatment approaches in medicine.

Artificial Intelligence and Machine Learning Tools and Technologies in Drug Discovery

Overview of popular artificial intelligence/machine learning platforms and software used in drug discovery

Numerous AI and ML platforms are transforming drug discovery by enhancing efficiency and accuracy. Notable companies include:

Atomwise

Utilizing its AtomNet platform, Atomwise employs DL to conduct structure-based drug design, screening over three trillion compounds to identify potential drug candidates.

Insilico medicine

Their Pharma.AI suite integrates AI across various stages of drug discovery, from target identification to clinical trial design. Insilico's approach has led to the first AI-discovered drug entering clinical trials.

Benevolent artificial intelligence

This platform combines multi-modal data to predict novel drug targets and streamline the drug discovery process, focusing on complex diseases such as cancer and neurodegenerative disorders.

Iktos

Known for its Dock AI and Makya platforms, Iktos accelerates small molecule design and optimization using AI-driven methodologies.

AIDDISON™ by Sigma-aldrich

This software supports medicinal chemists through generative AI and advanced computational methods for effective molecular design and screening.

These platforms exemplify the growing trend of integrating AI technologies into pharmaceutical research, significantly improving the drug discovery pipeline.^[10]

Role of neural networks, natural language processing, and reinforcement learning

Neural networks are pivotal in drug discovery as they excel at recognizing patterns in complex data. For instance, DL models can analyze chemical structures and biological data to predict interactions between drugs and targets, enhancing the identification of promising candidates.

Natural Language Processing (NLP) plays a vital role in extracting insights from vast amounts of unstructured data, such as scientific literature and clinical trial reports. NLP algorithms can summarize findings, identify relevant studies, and even suggest new hypotheses based on existing knowledge.

Reinforcement learning is increasingly being applied to optimize various aspects of drug development. This approach allows algorithms to learn from feedback in dynamic environments, making it particularly useful for optimizing clinical trial designs by identifying the most effective strategies for patient recruitment and treatment protocols.^[11]

Advantages and challenges of using artificial intelligence/machine learning tools in drug development

The advantages of utilizing AI/ML tools in drug development are significant:

Increased efficiency

AI accelerates the drug discovery process by automating tasks such as compound screening and target identification, reducing timeframes from years to months.

Cost reduction

By streamlining processes and improving predictive accuracy, AI can lower the overall costs associated with drug development.

Enhanced predictive power

ML models can analyze vast datasets to predict drug efficacy and safety more accurately than traditional methods.

However, challenges remain

Data quality and availability

The effectiveness of AI models heavily relies on high-quality data. Incomplete or biased datasets can lead to inaccurate predictions.

Integration with existing systems

Incorporating AI tools into established workflows can be complex, requiring significant changes in processes and training for personnel.

Regulatory hurdles

The use of AI in drug discovery raises questions about regulatory compliance, particularly regarding the validation of AI-generated results in clinical settings.

Addressing these challenges is crucial for maximizing the potential of AI/ML technologies in revolutionizing drug discovery.^[12]

Case Studies and Success Stories

Real-world examples of artificial intelligence/machine learning – Driven drug discovery successes

Several notable case studies illustrate the successful application of AI and ML in drug discovery. One prominent example is Insilico Medicine, which utilized its AI platforms to predict a molecule for the DDR1 target in just 21 days. This rapid identification was validated through *in vitro* and *in vivo* studies, showcasing the potential of AI to expedite the discovery process significantly. In addition, Insilico's

AI-designed drug candidate successfully passed Phase 1 trials within 30 months, a remarkable achievement compared to the typical 4 to 7 years required for traditional drug development.

Another success story involves Deep Genomics, which announced the industry's first AI-discovered therapeutic candidate, DG12P1, for Wilson's disease. The company's AI platform identified a specific genetic mutation and designed a corrective compound within 18 months, demonstrating how AI can streamline and enhance drug development timelines.^[13]

Benevolent AI has also made significant strides by leveraging its knowledge graph and AI-driven platform to identify novel drug targets and repurpose existing drugs. This approach has led to several promising drug candidates entering clinical trials, illustrating the efficacy of AI in transforming the pharmaceutical landscape.

Highlighting breakthrough drugs or therapies developed using artificial intelligence/machine learning technology

The breakthroughs achieved through AI/ML technologies are noteworthy. For instance, Takeda Pharmaceutical Co. invested \$4 billion in an AI-selected drug compound for psoriasis, which was identified by AI within just 6 months a process that would typically take years through conventional methods. Furthermore, molecules discovered using AI have shown significantly higher success rates in clinical trials, with Phase 1 trials reporting success rates between 80%–90%, compared to historical averages of 40%–65% for traditionally discovered drugs.

In addition, the software eToxPred, developed by researchers at Limeng Pu *et al.*, accurately predicted toxic properties of various compounds in over 72% of cases, potentially reducing the need for extensive clinical trials.^[14] These examples highlight how AI/ML technologies are not only accelerating drug discovery but also improving the quality and safety of new therapies.

Impact of artificial intelligence/machine learning on reducing development timelines and costs

The integration of AI and ML into drug discovery processes has led to significant reductions in both development timelines and costs. By automating tasks such as compound screening and data analysis, these technologies streamline workflows that traditionally took years. For example, Insilico Medicine's ability to move from target identification to clinical trials in a fraction of the usual time illustrates this efficiency gain.

Moreover, predictive analytics powered by ML help prioritize compounds based on their likelihood of success, thus focusing resources on the most promising candidates. This targeted approach not only accelerates development but also minimizes unnecessary expenditure associated with less viable options. Overall, the adoption of AI/ML tools is reshaping the pharmaceutical industry by enhancing

productivity and reducing costs, paving the way for more efficient drug development pipelines.

Challenges and Limitations

Data quality, availability, and integration issues

A significant challenge in AI-driven drug discovery is the quality and availability of data. Despite the vast amounts of data generated within the healthcare sector, accessing high-quality and diverse datasets remains problematic. Many existing datasets are not standardized, lack comprehensive metadata, or contain gaps that can compromise their validity. This lack of quality data can severely hinder the accuracy and reliability of AI algorithms, leading to erroneous predictions and potentially costly mistakes in drug development.

Furthermore, integrating data from various sources such as electronic health records, genomics, and clinical trial results poses substantial hurdles. The complexity of managing diverse data formats and ensuring consistency across datasets complicates the analysis process. Without effective integration strategies, researchers may struggle to leverage the full potential of AI technologies in drug discovery, ultimately impacting the development of new therapeutics.^[15]

Bias and overfitting in artificial intelligence/machine learning models

Bias in AI/ML models is a critical concern that can lead to skewed results in drug discovery. If the training datasets are unrepresentative due to demographic disparities or underrepresentation of certain populations, the resulting models may produce inaccurate predictions that do not generalize well to broader populations. This bias can adversely affect treatment efficacy and safety for diverse patient groups.

In addition, overfitting is a common issue where models perform exceptionally well on training data but fail to deliver accurate predictions on new, unseen data. This limitation can result in models that are overly complex and tailored to specific datasets rather than being robust across different scenarios. To mitigate these risks, it is essential for researchers to ensure diverse training datasets and apply techniques such as cross-validation to enhance model generalizability.^[16]

Regulatory challenges and the need for validation in clinical settings

The integration of AI into drug discovery raises several regulatory challenges that must be addressed for successful implementation. Regulatory agencies often lag behind technological advancements, leading to uncertainties regarding compliance and validation processes for AI-generated results. For AI models to gain acceptance in clinical settings, they must demonstrate reliability and efficacy through rigorous validation against high-quality clinical data.

Moreover, the interpretability of AI models is crucial for regulatory approval. Many complex AI algorithms operate as “black boxes,”

making it difficult for researchers and regulators to understand how decisions are made. This lack of transparency can hinder trust among stakeholders and complicate the approval process for new therapeutics developed using AI technologies. Establishing clear guidelines for validating AI-driven drug development processes is essential to facilitate their adoption while ensuring patient safety.

Ethical concerns surrounding the use of artificial intelligence in medicine

The use of AI in drug discovery raises several ethical concerns, particularly regarding data privacy and bias. The reliance on large-scale patient data necessitates stringent measures to protect patient confidentiality while allowing sufficient access for research purposes. Ethical considerations also extend to algorithmic bias; if training datasets are biased or unrepresentative, the resulting predictions may perpetuate inequalities in healthcare access and treatment outcomes.

Furthermore, there are concerns about accountability when using AI systems for decision-making in medicine. The opacity of many AI algorithms complicates efforts to ensure responsible use and raises questions about who is liable when errors occur due to flawed predictions. As AI technologies become increasingly integrated into healthcare, it is vital to navigate these ethical implications carefully to uphold patient rights and ensure equitable access to new therapies.^[17]

Future Directions and Emerging Trends

The growing role of artificial intelligence in personalized medicine and precision drug development

AI is increasingly recognized for its transformative potential in personalized medicine and precision drug development. By leveraging advanced algorithms, AI can analyze large datasets to identify novel predictive biomarkers that help tailor treatments to individual patients. For instance, platforms like Ocean Genomics utilize AI to pinpoint mRNA variants that indicate a patient's expected response to specific drugs, thus facilitating the development of personalized therapies. Similarly, Certis Oncology Solutions' Certis AI platform employs big data and ML to enhance treatment strategies by studying predictive biomarkers, ultimately improving drug success rates. The effectiveness of these AI applications hinges on the integration of vast amounts of high-quality data, which enhances decision-making capabilities and accelerates the development of tailored treatment options.

Integration of multi-omics data in artificial intelligence-driven drug discovery

The integration of multi-omics data including genomics, proteomics, metabolomics, and transcriptomics is becoming essential in AI-driven drug discovery. By combining diverse data types, researchers can gain a comprehensive understanding of individual variability in genes, environment, and lifestyle, paving the way for more effective personalized therapies. This holistic approach enables the identification of targeted therapies that can predict improved response

rates compared to traditional methods. AI technologies are crucial for analyzing these complex datasets, allowing for the identification of patterns that inform drug design and patient-specific treatment protocols. The convergence of multi-omics data with AI not only enhances the precision of drug development but also supports the personalization of prevention and treatment strategies across various medical disciplines.

Advancements in quantum computing and their potential impact on drug discovery

The emergence of quantum computing holds significant promise for revolutionizing drug discovery processes. Quantum computers have the potential to perform complex calculations at unprecedented speeds, enabling researchers to simulate molecular interactions and chemical reactions more efficiently than classical computers can achieve. This capability could drastically reduce the time required for drug discovery by facilitating rapid screening of potential compounds and optimizing molecular designs. As quantum computing technology matures, its integration with AI could lead to breakthroughs in understanding complex biological systems and accelerating the development of novel therapeutics.^[18]

Collaboration between artificial intelligence experts and pharmaceutical companies

The future of drug discovery is increasingly characterized by collaboration between AI experts and pharmaceutical companies. Such partnerships are essential for harnessing the full potential of AI technologies in developing new drugs. Pharmaceutical companies benefit from the expertise of data scientists and AI specialists who can apply advanced analytical techniques to large datasets generated during research and clinical trials. Collaborative efforts enable companies to integrate AI into their workflows effectively, enhancing their ability to identify promising drug candidates and optimize clinical trial designs.

Moreover, these collaborations can lead to innovative approaches in personalized medicine, where tailored therapies are developed based on individual patient data analyzed through AI algorithms. As both sectors continue to evolve, fostering strong partnerships will be crucial for driving advancements in drug discovery and ensuring that new therapies meet the specific needs of diverse patient populations.^[19]

Conclusion

AI and ML are reshaping drug discovery by enhancing efficiency, accuracy, and cost-effectiveness across the entire development pipeline. While significant progress has been made, challenges related to data quality, model bias, and regulatory approval must still be addressed. The future of drug discovery lies in the continued integration of AI/ML with emerging technologies such as quantum computing and multi-omics data, paving the way for personalized and precision medicine. Ongoing innovation, coupled with ethical

considerations, will be crucial in realizing the full potential of AI/ML in transforming pharmaceutical research and development.

References

1. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. *Alzheimers Dementia* (NY) 2017;3:651-7.
2. Blanco-González A, Cabezon A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, *et al.* The role of AI in drug discovery: Challenges, opportunities, and strategies. *Pharmaceuticals* (Basel) 2023;16(6):891.
3. Han R, Yoon H, Kim G, Lee H, Lee Y. Revolutionizing medicinal chemistry: The application of artificial intelligence (AI) in early drug discovery. *Pharmaceuticals* (Basel) 2023;16:1259.
4. Holmes J, Sacchi L, Bellazzi R. Artificial intelligence in medicine. *Ann R Coll Surg Engl* 2004;86:334-8.
5. Rahmani AM, Yousefpoor E, Yousefpoor MS, Mehmood Z, Haider A, Hosseinzadeh M, *et al.* Machine learning (ML) in medicine: Review, applications, and challenges. *Mathematics* 2021;9:2970.
6. Helm JM, Swiergosz AM, Haeberle HS, Karnuta JM, Schaffer JL, Krebs VE, *et al.* Machine learning and artificial intelligence: Definitions, applications, and future directions. *Curr Rev Musculoskeletal Med* 2020;13:69-76.
7. Wang S, Sim TB, Kim YS, Chang YT. Tools for target identification and validation. *Curr Opin Chem Biol* 2004;8:371-7.
8. Nicolaou CA, Brown N. Multi-objective optimization methods in drug design. *Drug Discov Today Technol* 2013;10:e427-35.
9. Newman DJ, Cragg GM. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. *Curr Med Chem* 2004;11:1693-713.
10. Niazi SK. The coming of age of AI/ML in drug discovery, development, clinical testing, and manufacturing: The FDA perspectives. *Drug Des Devel Ther* 2023;17:2691-725.
11. Goldberg Y. *Neural Network Methods in Natural Language Processing*. California: Morgan and Claypool Publishers; 2017.
12. Khadela A, Popat S, Ajabiya J, Valu D, Savale S, Chavda VP. AI, ML and other bioinformatics tools for preclinical and clinical development of drug products. In: *Bioinformatics Tools for Pharmaceutical Drug Product Development*. United States: Wiley Publishing Company; 2023. p. 255-84.
13. Yoo J, Kim TY, Joung I, Song SO. Industrializing AI/ML during the end-to-end drug discovery process. *Curr Opin Struct Biol* 2023;79:102528.
14. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: A review. *AAPS J* 2022;24:19.
15. Batini C, Scannapieco M. Data quality issues in data integration systems. In: *Data and Information Quality: Dimensions, Principles and Techniques*. Germany: Springer; 2016. p. 279-307.
16. Al-Zaiti SS, Alghwiri AA, Hu X, Clermont G, Peace A, Macfarlane P, *et al.* A clinician's guide to understanding and critically appraising machine learning studies: A checklist for ruling out bias using standard tools in machine learning (ROBUST-ML). *Eur Heart J Digit Health* 2022;3:125-40.
17. McCradden MD, Baba A, Saha A, Ahmad S, Boparai K, Fadaiefard P, *et al.* Ethical concerns around use of artificial intelligence in health care research from the perspective of patients with meningioma, caregivers and health care providers: A qualitative study. *Canad Med Assoc Open Access J* 2020;8:E90-5.
18. Cong Y, Endo T. Multi-omics and artificial intelligence-guided drug repositioning: Prospects, challenges, and lessons learned from COVID-19. *OMICS* 2022;26:361-71.
19. Kearney C. Emerging markets research: Trends, issues and future directions. *Emerg Mark Rev* 2012;13:159-83.